December 25, 2014 5:52 AM ET

Life Sciences Tools and Services

Company Overview of Gallus Biopharmaceuticals, LLC

Company Overview

Gallus Biopharmaceuticals, LLC provides biopharmaceutical contract development and manufacturing services. The company offers process development, analytical method development, process validation, quality/regulatory, cGMP manufacturing, fill/finish, and project management services, as well as stability, cell banking, and storage services. It also manufactures mammalian biopharmaceutical products. The company was founded in 2010 and is headquartered in St. Louis, Missouri with a location in Princeton, New Jersey. As of September 30, 2014, Gallus Biopharmaceuticals, LLC operates as a subsidiary of DPx Holdings B.V.

4766 LaGuardia Drive

St. Louis, MO 63134-3117

United States

Founded in 2010

Phone:

314-426-5000

Fax:

314-733-3888

Key Executives for Gallus Biopharmaceuticals, LLC

Founder and Chief Financial Officer
Chief Manufacturing Officer
Senior Director of Human Resources
Senior Vice President of Business Development
Compensation as of Fiscal Year 2014.

Gallus Biopharmaceuticals, LLC Key Developments

Gallus Biopharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:45 PM

Gallus Biopharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:45 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Gallus Biopharmaceuticals, LLC Presents at BIO-Europe 2014, Nov-04-2014 05:15 PM

Gallus Biopharmaceuticals, LLC Presents at BIO-Europe 2014, Nov-04-2014 05:15 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Gallus BioPharmaceuticals, LLC Enters Cell Line Optimization and Manufacturing Agreement with Omni Bio Pharmaceutical, Inc

Gallus BioPharmaceuticals, LLC and Omni Bio Pharmaceutical, Inc. jointly announced finalization of a multi-stage manufacturing services agreement. The agreement includes cell line optimization, analytical development and manufacturing scale-up activities for Omni Bio's leading AAT Fc fusion protein with the goal of providing cGMP product to support animal toxicology studies and early clinical trials of the molecule. Under the agreement, Omni Bio has selected the commercially available CHOZN(R) GS Cell line as the expression system. In addition, SAFC(R) will perform the cell line development and safety testing services, in conjunction with Gallus' overall management of the process development and manufacturing services program for Omni Bio. AAT is the most abundant circulating serine protease inhibitor in the body and an acute phase reactant. Systemic deficiency in AAT due to genetic mutations can result in debilitating liver failure and chronic lung disease such as emphysema. Lifelong treatment with plasma-derived AAT, intravenously administered, is indicated for such patients. Recent evidence suggests that AAT plays an important role in modulating immunity, inflammation and apoptosis. AAT protects various cell types from cell death, inhibits caspases-1 and -3 activity and has been shown to be effective in a wide variety of animal models of human disease, including diabetes, graft versus host disease (rejection reactions following bone marrow or other transplantation procedures), refractory gout, myocardial infarction and inflammatory bowel disease.

Similar Private Companies By Industry

Company Name Region
Kailos Genetics, Inc. United States
ResearchDx, LLC United States
BioAgilytix Labs, Inc. United States
Prologue Research International, Inc. United States
Waubun Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 27, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Gallus Biopharmaceuticals, LLC, please visit gallusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.